West Pharmaceutical Services’ first quarter results drew a negative market response, despite the company surpassing Wall Street’s revenue and non-GAAP profit expectations. Management attributed the flat year-over-year sales to continued destocking in biologics components and a shift in demand to specific manufacturing sites, creating short-term supply constraints. CEO Eric Green highlighted that “solid contributions from GLP-1s and a reduced impact from industry-wide destocking” were positive factors, but also pointed to ongoing mix challenges. Outgoing CFO Bernard Birkett noted improved operating efficiencies and cost controls, partially offsetting the effects of changes in product and segment mix.
Is now the time to buy WST? Find out in our full research report (it’s free).
West Pharmaceutical Services (WST) Q1 CY2025 Highlights:
- Revenue: $698 million vs analyst estimates of $684.5 million (flat year on year, 2% beat)
- Adjusted EPS: $1.45 vs analyst estimates of $1.23 (18.1% beat)
- Adjusted EBITDA: $165 million vs analyst estimates of $150.6 million (23.6% margin, 9.6% beat)
- The company lifted its revenue guidance for the full year to $2.96 billion at the midpoint from $2.89 billion, a 2.4% increase
- Management raised its full-year Adjusted EPS guidance to $6.25 at the midpoint, a 2.5% increase
- Operating Margin: 15.3%, down from 17.7% in the same quarter last year
- Market Capitalization: $15.66 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions West Pharmaceutical Services’s Q1 Earnings Call
- Paul Knight (KeyBanc): asked about utilization rates at the new Dublin site and margin improvements. CEO Eric Green explained utilization is low but ramping, and Birkett attributed margin gains to operational efficiencies and lighter SG&A spending.
- Larry Solow (CJS Securities): questioned the drivers behind softer high-value product growth and the impact of government spending reductions. Birkett noted supply constraints and slightly weaker pricing, while Green said no macroeconomic or policy changes have significantly affected demand.
- Justin Bowers (Deutsche Bank): inquired whether increased demand would spill into 2026 and how tariffs impact sourcing. Green confirmed some demand could shift to next year, and Birkett said tariffs affect both components and finished goods, with mitigation efforts ongoing.
- David Windley (Jefferies): asked about margin offsets from product mix and the economics of AnnexOne, as well as leadership transitions. Birkett said efficiencies and AnnexOne upgrades help margins, and Green described management changes as a natural evolution.
- Patrick Donnelly (Citi): focused on the high-value component ramp and tariff pass-through. Green reported improving order trends and destocking relief, while Birkett said tariff cost offsets are not yet embedded in guidance.
Catalysts in Upcoming Quarters
Looking ahead, our team will monitor (1) the pace of biologics demand recovery and the trajectory of high-value component orders, (2) progress on efficiency gains and automation, particularly with the SmartDose platform, and (3) management’s ability to mitigate tariff headwinds through cost pass-throughs or operational adjustments. Execution on new contract manufacturing wins and expansion in AnnexOne projects will also be critical signposts.
West Pharmaceutical Services currently trades at $218.87, in line with $217.68 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
